subject inclusion question in replicate design for ANVISA [RSABE / ABEL]

posted by Helmut Homepage – Vienna, Austria, 2019-09-04 20:23  – Posting: # 20542
Views: 518

Hi Shuanghe,

» […] the client's statistical consultant commented that only subjects who complete all 4 period (2T+2R) should be included, otherwise, they should be excluded even if they completed 3 period.

IMHO, this doesn’t make sense. See the example in the vignette of replicateBE. At least this is what I have I done in my European studies and never got a question about it.

» By the way, Helmut, does this belong to Study Assessment or Regulative/Guideline category?

Study Assessment is about ongoing/completed studies. I moved it here.

Cheers,
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. ☼
Science Quotes

Complete thread:

Activity
 Mix view
Bioequivalence and Bioavailability Forum |  Admin contact
20,008 posts in 4,231 threads, 1,377 registered users;
online 11 (1 registered, 10 guests [including 9 identified bots]).
Forum time (Europe/Vienna): 00:10 CET

The plural of anecdote is data.    Raymond Wolfinger

The BIOEQUIVALENCE / BIOAVAILABILITY FORUM is hosted by
BEBAC Ing. Helmut Schütz
HTML5